ANGLE plc  

(Public, LON:AGL)   Watch this stock  
Find more results for Andrew Angle�
-0.70 (-0.87%)
Mar 27 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 78.60 - 80.15
52 week 53.70 - 99.00
Open 80.25
Vol / Avg. 168,779.00/295,279.00
Mkt cap 46.57M*
P/E     -
Div/yield     -
EPS -0.05*
Shares 45.24M
Beta     -
Inst. own     -

Key stats and ratios

Q4 (Oct '14) 2014
Net profit margin -557.64% -154.56%
Operating margin -560.07% -168.54%
EBITD margin - -315.61%
Return on average assets -58.34% -18.10%
Return on average equity -56.12% -16.35%
Employees 28 -
CDP Score - -


The Surrey Research Park 3 Frederick Sanger Road
United Kingdom - Map
+44-1483-685830 (Phone)
+44-1483-685836 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Angle plc is a specialist medical diagnostic company with products in cancer diagnostics and foetal health. The Company�s product is the Parsortix cell separation system, which can capture rare cells from blood. The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient�s cancer for personalised cancer care. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The Parsortix system can handle blood volume of less than 1 milliliter and up to 50 milliliters enabling a range of applications. It can be used with all solid tumor cancers including breast, prostate, lung, and colorectal and is biomarker compatible.

Officers and directors

Andrew D. W. Newland Chief Executive, Executive Director
Ian F. Griffiths Finance Director, Company Secretary, Executive Director
Garth R. Selvey Non-Executive Chairman of the Board
Age: 59
Brian Howlett Non-Executive Director
David W. Quysner CBE Non-Executive Independent Director
Age: 67